RESULTS
a r t i c l e s
A common cellular pathology for many diabetic vascular complications is an enhanced rate of cellular apoptosis as observed in retinal pericytes, renal podocytes and vascular endothelial cells 1, 2 . Hyperglycemia, the major risk factor for diabetic microvascular complications 3 , is responsible for inducing apoptosis in these vascular tissues directly 4 or indirectly 5, 6 by altering cytokine expression and leading to the accumulation of toxic products in organs affected by diabetes. Although intensive insulin treatment in individuals with diabetes can delay the onset and progression of diabetic complications 3 , initiation of intensive glycemic control after periods of poor glycemia does not substantially decrease the rate of progression of retinopathy and other microvascular diseases, suggesting that hyperglycemia-induced chronic cellular changes are difficult to reverse 7 . To clarify the biochemical mechanisms involved in hyperglycemiainduced cellular apoptosis, we characterized the signaling cascade of hyperglycemia leading to pericyte apoptosis in diabetic retinopathy, the most specific vascular pathology attributed to diabetes, which may represent a common pathway for other microvascular abnormalities in diabetes 8, 9 .
Noteworthy recent findings implicate a role of PDGF receptor-β (PDGFR-β) in pericyte apoptosis. PDGF-B or PDGFR-β deficient mice show retinal pericyte depletion associated with the development of microaneurysms and acellular capillaries as a result of both pericyte and endothelial cell death, recapitulating the early changes of diabetic retinopathy 10 . However, it is unclear whether pericyte loss results from decreased PDGF-B abundance, as the expression of PDGF-B in the retina is increased in diabetic compared to nondiabetic rats 11 . In addition, although oxidative stress and activation of NF-κB have been reported to be involved in hyperglycemia-induced cell apoptosis, the interrelationship between PDGF-B inhibition and oxidative stress in mediating pericyte apoptosis and the initiation of diabetic retinopathy is not known. In investigating the mechanisms by which hyperglycemia induces pericyte apoptosis, we have uncovered a new signaling pathway by which hyperglycemia induces vascular damage: activation of PKC-δ and p38α MAPK, leading to increased expression of the protein tyrosine phosphatase (PTP) SHP-1, which, in turn, leads to the dephosphorylation of PDGFR-β. a r t i c l e s respectively) in membrane fractions of isolated retinal microvessels (Fig. 1b) and whole retina (Supplementary Fig. 1a ). PKC-δ activation induces apoptosis in other cell types 13 . Therefore, we evaluated retinal vascular changes in nondiabetic and diabetic PKC-δ-null (Prkcd -/-) and age-matched control (Prkcd +/+ ) mice with or without interventional glycemic control with insulin implants. Six months after the streptozotocin treatment used to induce diabetes, Prkcd +/+ and Prkcd -/-diabetic mice had lower body weights and plasma insulin levels but increased glucose concentrations compared with nondiabetic mice with a similar genetic background ( Supplementary  Fig. 1b) . Treatment of the diabetic mice using insulin implants for the last 3 months of the experiment normalized their body weight and glucose level but not their hyperinsulinemia (Supplementary Table 1 ). Histological analyses of the retina showed that diabetes increased the number of acellular capillaries by 59% (P < 0.05) (Fig. 1c) and the combined numbers of acellular capillaries and pericyte loss (ghosts) (Supplementary Fig. 1c,d ) in Prkcd +/+ but not Prkcd -/-mice as compared to nondiabetic Prkcd +/+ mice. Reduction in blood glucose levels for the last 3 months of the experiment did not prevent the increase in the number of acellular capillaries in Prkcd +/+ mice (Fig. 1c) .
Endothelial-specific PDGF-B-deficient mice show pericyte loss, microaneurysm formation and acellular capillaries in the retina 10 . In view of our findings that PKC-δ activation also leads to these types of retinal vascular defects, we evaluated whether the ability of PDGF-B to activate the protein kinases extracellular signalrelated kinase (ERK) and Akt in the retina is affected by PKC. After intravitreous injection of PDGF-BB (dimeric PDGF composed of two B chains), the levels of phospho-ERK and phospho-Akt in the retina of nondiabetic Prkcd +/+ mice and nondiabetic and diabetic Prkcd -/-mice increased by 1.6-to 2.1-fold (P < 0.05) but remained unchanged in diabetic Prkcd +/+ mice (Fig. 1d) . Vascular endothelial growth factor (VEGF), PDGF-B, PKC-β and PKC-δ mRNA or protein expression increased in isolated retinal microvessels (Fig. 1e,f) and in whole retina ( Supplementary Fig. 2a-c ) of diabetic as compared with nondiabetic Prkcd +/+ mice by 2.4-to 2.9-fold (0.001 < P < 0.05). Normalization of blood glucose concentrations did not prevent the increases in PDGF-B or PKC-δ protein or mRNA expression induced by diabetes ( Supplementary Fig. 2a-c) . Consistent with the histological retinal findings, PDGF-B, PKCβ and VEGF protein and mRNA expression were not higher in diabetic Prkcd -/-mice as compared to nondiabetic Prkcd -/-mice (Fig. 1e,f and Supplementary  Fig. 2a-c) . Moreover, phosphorylation of PKC-δ (on Tyr311) was higher in diabetic as compared with nondiabetic Prkcd +/+ mice, confirming activation of the PKC-δ isoform in retinas of diabetic mice (Supplementary Fig. 2a ). Diabetic Prkcd +/+ but not Prkcd -/-mice showed increased leakage and permeability (P = 0.038) compared to nondiabetic Prkcd +/+ , as assessed by flat mounts of retinas injected with FITC-dextran (Fig. 1g) and Evans blue (Fig. 1h) . Prkcd +/+ mice after 4 weeks of diabetes had a 46% reduction of retinal blood flow (RBF) (P < 0.05) and a 78% increase in mean circulation time (MCT) (P < 0.01) as compared to nondiabetic Prkcd +/+ mice ( Supplementary  Fig. 3a,b) . Notably, diabetic Prkcd −/− mice also showed a decrease 
(e,f) Expression of VEGF and PDGF (e) and PKC-β and PKC-δ (f) mRNA in isolated microvessels from NDM and DM Prkcd +/+ or Prkcd -/-mice (n = 6).
(g,h) Flat mounts of retinas infused with FITC-dextran (g) and permeability assay using Evans blue dye (n = 8) (h). Results are shown as means ± s.d. of three or four independent experiments. *P < 0.05 versus NDM Prkcd +/+ mice. Fig. 3a,b) . The alteration of RBF in mice by hyperglycemia seems to be transient, as blood flow returned to basal levels after a 2-month period of diabetes (Supplementary Fig. 3c ). Although hyperglycemia-induced endothelin-1 (ET-1) expression in the retina is related to retinal abnormalities 14 , transgenic mice overexpressing ET-1 showed decreased RBF ( Supplementary Fig. 3d ) but did not develop vascular pathologies even after 12 months of age (data not shown). These results suggest that early changes of slowed RBF may not predict development of diabetic retinopathy.
Effects of high glucose on PKC- and PDGF-B signaling
To identify the mechanisms by which glucose levels and PKC-δ isoform activation may inhibit PDGF-B action and increase pericyte apoptosis, we developed a cultured bovine retinal pericyte (BRPC) model that mimics the chronic effects of hyperglycemia on retinal pericyte pathology (Supplementary Fig. 4a ). Exposure of BRPCs to a high concentration of glucose (20 mM; 'high glucose') for 72 h increased DNA fragmentation by twofold (P < 0.01) and increased annexin V marker abundance by 11.6% as compared to a low concentration of glucose (5.6 mM; 'low glucose') ( Fig. 2a and Supplementary  Fig. 4b ). Decreasing the glucose concentration from high to low for an additional period of 3 d did not prevent pericyte apoptosis (Fig. 2a) . Stimulation with PDGF-BB decreased DNA fragmentation by 31% (P < 0.05) in the low-glucose condition. However, PDGF-BB did not prevent high glucose-induced DNA fragmentation, even when tested on BRPCs that had been switched to low glucose levels for an additional period of 3 days (Fig. 2a) . Retinal pericytes isolated from Sprague-Dawley rats that had been rendered diabetic for three months retained an elevated level of apoptosis when cultured either in lowglucose or high-glucose conditions as compared to retinal pericytes isolated from nondiabetic rats (Supplementary Fig. 4c ). Incubation of BRPCs in high-glucose or in high-glucose followed by low-glucose conditions increased expression of proapoptotic molecules such as cleaved caspase-3 and Bax and decreased the expression of the antiapoptotic protein Bcl-2 as compared to incubation in low-glucose conditions ( Supplementary Fig. 4d ). PDGF-BB increased DNA synthesis by 2.5-fold (P < 0.01) in BRPCs at low glucose concentrations; this effect was inhibited by 100% when pericytes were exposed to highglucose and PDGF-B conditions for 3 d (Supplementary Fig. 4e ).
In situ total PKC activity and PKC-δ activity in BRPCs increased by 100% and 30%, respectively (P < 0.05), in a time-dependent manner after 72 h of exposure to high glucose and remained elevated after the cells were switched to low-glucose conditions ( Fig. 2b and Supplementary Fig. 5a ). Immunoblot analyses showed that PKC-δ was translocated from the cytosol to the membrane fraction when pericytes were incubated with high glucose (39%, P < 0.05) and remained in the membrane fraction even when the cells were returned to low glucose conditions (Fig. 2c) . The total amount of diacylglycerol, an activator of PKCs, increased by 2.3-fold (P < 0.05) in BRPCs exposed to high-glucose conditions for 72 h (Fig. 2d) . In contrast to PKC activation, switching BRPCs from high-to low-glucose conditions did reverse the increase in diacylglycerol levels (Fig. 2d) . Although the half-life of PKC-δ mRNA, as determined in experiments using actinomycin D, was not affected by high glucose compared to low glucose, PKC-δ mRNA levels increased by 2.7-fold (P < 0.05) when pericytes were exposed to high glucose, an effect that was not reversed by changing to low glucose ( Supplementary Fig. 5b,c) .
To determine whether PKC-δ has a causal role in pericyte apoptosis and in the inhibition of PDGF-B actions, we transfected BRPCs with a control adenoviral vector expressing GFP (Ad-GFP) or with adenoviral vectors expressing either dominant-negative (Ad-DN) or wild-type (Ad-WT) PKC-δ isoforms. Pericytes transfected with Ad-GFP responded to high glucose similarly to untransfected cells, with a twofold increase in DNA fragmentation (0.001 < P < 0.05) (Fig. 2e) . Transfection of Ad-WT PKC-δ but not Ad-WT PKC-β 2 increased DNA fragmentation by 30% and 50% (P < 0.05) in low-glucose and a r t i c l e s high-glucose conditions, respectively, whereas transfection of Ad-DN PKC-δ prevented the effects of high glucose on DNA fragmentation (Fig. 2e  and Supplementary Fig. 5d ). Moreover, brain pericytes isolated from diabetic Prkcd +/+ mice, but not from diabetic Prkcd -/-mice, showed increased DNA fragmentation as compared to brain pericytes isolated from nondiabetic Prkcd +/+ mice (Supplementary Fig. 5e ). In low glucose conditions, PDGF-BB activated ERK and Akt phosphorylation in BRPCs by three-and fourfold (P < 0.001), respectively (Fig. 2f) . These effects of PDGF-BB were impaired by 79-100% and by 67-100% in Ad-GFP-and Ad-WT PKC-δ-transfected pericytes when exposed to high-glucose as compared to low-glucose conditions, respectively, effects that were completely reversed in cells transfected with Ad-DN PKC-δ (Fig. 2f) .
p38 MAPK is a target for high glucose effects
Because p38 MAPK expression induced by PKC-δ activation can cause cellular apoptosis 5,15 , we explored whether p38 MAPK is involved in high glucose-dependent inhibition of PDGF signaling. High glucose induced p38 MAPK phosphorylation in BRPCs by 2.8-fold (P < 0.001), and this was not reversed by an additional 72-h exposure to low glucose (Fig. 3a) . Inhibition of p38 MAPK using the compound SB203580 prevented high glucose-induced pericyte apoptosis, prevented inhibition of DNA synthesis and Akt and ERK phosphorylation and restored the effects of PDGF-BB treatment ( Fig. 3b and Supplementary  Fig. 6a,b) . The α and β isoforms of p38 MAPK are the isoforms ubiquitously expressed in cells 16 . Immunoprecipitation studies in BRPCs exposed to low glucose, high glucose and high glucose plus low glucose showed that expression of p38α, but not p38β, was increased by high glucose conditions (Supplementary Fig. 6c ). Therefore, we explored the role of each p38 MAPK isoform using adenoviral vector containing a dominant-negative form of either the p38α (Ad-DN p38α) or p38β (Ad-DN p38β) isoform. Transfection of Ad-DN p38α MAPK completely prevented (P < 0.01) the action of high glucose on pericyte apoptosis (Fig. 3c) and reversed high glucose-induced inhibition of PDGF-BB-mediated induction of Akt and ERK phosphorylation (Fig. 3d) . Of note, transfection of Ad-DN p38β MAPK exacerbated the effects of high glucose on pericyte apoptosis and had no effect on the inhibition of PDGF-BB signaling (Fig. 3c,d ). Reactive oxygen species (ROS) can also be increased by hyperglycemia and cause cellular apoptosis 17 . BRPCs exposed to high-glucose conditions increased ROS production by 11% (P < 0.05), which was not reversed by switching the cells to low-glucose conditions (Fig. 3e) . However, treatment with N-acetylcysteine (NAC) only partially prevented high glucoseinduced pericyte apoptosis, by 47% (P < 0.05), whereas this treatment completely prevented H 2 O 2 -induced cellular apoptosis (Fig. 3f) . These results suggest that another pathway aside from oxidants is involved in hyperglycemia-induced pericyte apoptosis.
SHP-1 mediates PKC- and p38 MAPK actions on PDGFR-
In considering how activation of PKC-δ and p38α MAPK inhibit PDGF signaling, we decided to evaluate SHP-1, which can bind PDGFR-β and inhibit its activation 18 . In BRPCs, high glucose increased SHP-1 expression by 81% (P < 0.01), and this increase in SHP-1 expression persisted even after cells were shifted to low glucose-conditions (Fig. 4a) . Other PTPs, such as SHP-2 and PTP-1B, or lipid phosphatases, such as PTEN, were not affected (Fig. 4a) . Notably, retinal pericytes isolated from diabetic rats and cultured in either low-glucose or high-glucose conditions had significantly elevated levels of PKC-δ and p38 MAPK phosphorylation and of SHP-1 expression as compared to those isolated from nondiabetic rats (Fig. 4b) . In parallel, PKC-δ and SHP-1 mRNA expression in retinal pericytes isolated from diabetic rats were increased by 73% and 78%, respectively, compared to those isolated from nondiabetic rats, whereas expression of these genes was not affected in retinal endothelial cells, and ET-1 mRNA expression was elevated in both cell types by diabetes ( Supplementary  Fig. 7a) . We demonstrated the functional importance of PKC-δ and p38 MAPK activation on high glucose-induced SHP-1 expression by showing that SB203580 treatment or Ad-DN PKC-δ transfection completely 
prevented high glucose-induced SHP-1 protein expression (P < 0.05) ( Fig. 4c and Supplementary Fig. 7b ). Exposure of bovine retinal endothelial cells and BRPCs transfected with Ad-WT PKC-β to high glucose concentrations or the addition of H 2 O 2 (100 µM) to BRPCs did not increase SHP-1 protein expression as compared to control conditions ( Supplementary Fig. 7c-e) . SHP-1 phosphatase activity increased in BRPCs by 57% (P < 0.01) with high glucose exposure and was not reversed by switching the cells to low-glucose conditions ( Supplementary  Fig. 8a) ; however, SHP-1 activity was reduced by 77% (P < 0.01) or 86% (P < 0.05) in cells treated with SB203580 (Supplementary Fig. 8a ) or transfected with Ad-DN PKC-δ (Fig. 4d) , respectively. To study the functional role of SHP-1 in hyperglycemia, we used siRNA and an adenoviral vector containing dominant-negative SHP-1 (Ad-DN SHP-1). Transfection of Ad-DN SHP-1 or knockdown of SHP-1 or PKC-δ with siRNA in BRPCs not only completely inhibited high glucose-induced apoptosis but also restored the antiapoptotic and signaling actions of PDGF-BB as compared to GFP siRNA-or Ad-LacZ-transfected cells (Fig. 4e-g and Supplementary Fig. 8b ). Our data also showed that high-glucose conditions increased the expression of cleaved caspase-8, and that transfection of either Ad-DN PKC-δ or Ad-DN SHP-1 prevented these effects (Supplementary Fig. 8c) . These results may in part explain why inhibition of the PKC-δ-p38α MAPK-SHP-1 pathway in cultured cells can prevent pericyte apoptosis in high-glucose conditions alone. The levels of PKC-δ and p38 MAPK phosphorylation and of SHP-1 expression were also increased in brain pericytes isolated from diabetic Prkcd +/+ but not Prkcd -/-mice compared those isolated from nondiabetic Prkcd +/+ mice (Fig. 4h) .
A specificity protein-1 (SP1) element is present in the promoter region of SHP-1 (ref. 19 ). We designed specific oligonucleotides to the SP1 sequence (GC box) located in the bovine SHP-1 promoter region to measure SP1 transcriptional binding activity. Exposure of BRPCs to high glucose increased SP1 binding activity in nuclear lysates, which could be suppressed by addition of either a SP1 inhibitor (mithramycin A), or non-biotin-labeled competitor oligonucleotides at a tenfold higher concentration than biotin-labeled DNA oligonucleotides of SP1; oligonucleotides with two mutations in the SP1 GC box sequence were used as a negative control (Fig. 4i) . SP1 binding activity was also elevated in high glucose-treated cells transfected with Ad-GFP and Ad-WT PKC-δ but not in high glucose-treated cells transfected with Ad-DN PKC-δ (Fig. 4j) . To confirm that hyperglycemia promotes SHP-1 expression by increasing the transcriptional activity of SP1, we treated BRPCs with mithramycin A, which prevented high glucose-induced SHP-1 expression as compared to vehicle (methanol)-treated or untreated cells (Supplementary Fig. 8d ). 
a r t i c l e s

SHP-1 expression is independent of NF-B activation
Activation of NF-κB has been reported to be involved in pericyte apoptosis induced by hyperglycemia 20 . Therefore, we evaluated the relationship between PKC-δ, p38α MAPK and SHP-1 activation, and NF-κB transcriptional activity. High glucose exposure of BRPCs increased the transcriptional activity of NF-κB in Ad-GFP-and Ad-WT PKC-δ-transfected cells by three-and fourfold (P < 0.001), respectively, but this effect was completely inhibited in Ad-DN PKC-δ-transfected pericytes (Fig. 5a) . NAC treatment also completely prevented NF-κB transcriptional binding activity induced by either high-glucose conditions or H 2 O 2 treatment ( Supplementary  Fig. 9 ). Furthermore, inhibition of p38 MAPK by SB203580 (10 µM) also prevented high glucose-induced NF-κB transcriptional activity (P < 0.001) (Fig. 5b) . Selective inhibitors of NF-κB translocation to the nucleus (SN50) or DNA binding (SM7368) partially reduced high glucose-induced DNA fragmentation by 60% and 52% (P < 0.01), respectively (Fig. 5c) . However, these compounds did not reverse the inhibitory actions of high glucose on PDGF's effects-either its antiapoptotic effects or its effects on the phosphorylation of ERK and Akt and on the phosphorylation of tyrosine residues of PDGFR-β (Fig. 5c,d) . Inhibition of NF-κB with either SN50 or SM7368 also did not prevent the high glucose-induced increase in SHP-1 expression (Fig. 5e) .
Retina
Renal 
SHP-1 and p38 MAPK inhibition in diabetic Prkcd -/-pericytes
We assessed SHP-1 expression in several relevant tissues including the retina and renal cortex in diabetic mice. Expression of SHP-1 protein increased in the retina by 1.8-to twofold (P < 0.05) after 3 or 6 months of diabetes and in the renal cortex by 1.8-fold (P < 0.05) after 3 months of diabetes (Fig. 6a,b) . Using laser capture microcopy, we found that the diabetic state increased SHP-1 mRNA expression in the retinal pigment epithelium (RPE) by fourfold (P = 0.05) and in vascular tissues by 2.1-fold (P = 0.03), but not in the retinal neuronal layers (Fig. 6c) . We also evaluated the role of PKC-δ and the reversibility of SHP-1 mRNA expression in the retina. Expression of SHP-1 mRNA increased in the retina of diabetic Prkcd +/+ mice after 6 months of diabetes (fourfold; P < 0.001) and remained elevated even after achieving euglycemia in the second 3-month period; however, SHP-1 mRNA expression was not different in diabetic Prkcd -/-mice as compared to nondiabetic controls (Fig. 6d) . SHP-1 and phospho-p38 MAPK protein expression were elevated by 51% and 50% (P < 0.01), respectively, in the retinas of diabetic Prkcd +/+ mice without and with treatment with insulin implants as compared to nondiabetic Prkcd +/+ mice (Fig. 6e) . In contrast, diabetic Prkcd -/-mice showed no changes in SHP-1 or phospho-p38 MAPK protein expression as compared to nondiabetic Prkcd -/-mice (Fig. 6e) . By immunostaining for NG2, a marker for pericytes, we found that pericytes in the retinal microvessels of diabetic mice had higher levels of PKC-δ and SHP-1 expression as compared to microvessel pericytes from nondiabetic mice (Fig. 6f) . In contrast, we did not find any apparent differences in the expression of PKC-δ or SHP-1 in retinal endothelial cells (as determined by staining for isolectin B4) between diabetic and nondiabetic mice (Fig. 6f) .
Diabetes has been associated with elevated amounts of oxidative stress markers and with increased degradation of IκBα, an inhibitor of NF-κB signaling 21 . Although cytosolic superoxide dismutase (SOD-1)-transgenic diabetic mice had reduced oxidative stress plasma marker abundance (data not shown) and unelevated expression of IκBα protein in the retina compared to nontransgenic control diabetic mice, they had increased SHP-1 expression by 87% (P < 0.05) as compared to nondiabetic transgenic mice, a similar finding as in nontransgenic mice (Fig. 6g) . These results suggest that elevated SHP-1 protein expression by hyperglycemia is not regulated by oxidative stress.
DISCUSSION
We have identified a series of common biochemical steps that are induced by hyperglycemia to activate NF-κB and PDGF-B resistance pathways to cause pericyte apoptosis, the most specific vascular histopathology associated with diabetic complications. These results show that hyperglycemia activates PKC-δ in a persistent manner, probably via an increase in transcription of the gene encoding PKC-δ. Hyperglycemia has previously been reported to increase PKC-β abundance in endothelial cells 22 , but the consequences of activation of these two PKC isoforms are very different: PKC-δ activation is associated with cellular apoptosis, whereas PKC-β activation is known to enhance cellular growth 12, 23 . Accordingly, we found that a sustained increase in PKC-δ levels for several months of diabetes correlated with the appearance of retinal pericyte apoptosis and acellular capillaries. In contrast, activation of PKC-β isoform in endothelial cells mediates an increase in ET-1 expression and enhances VEGF activity to cause endothelial dysfunction and to decrease RBF 24, 25 . Clinical trials showed that a PKC-β-selective inhibitor delays the loss of visual acuity and progression of diabetic macular edema but does not affect the progression of proliferative diabetic retinopathy 26 , suggesting that more than PKC-β activation is involved in the vascular pathology of diabetic retinopathy.
We found that hyperglycemia activates PKC-δ (but not PKC-β) specifically in pericytes, as shown using immunohistochemistry of retinal microvessels and pericytes isolated from diabetic rats. PKC-δ activation is required for pericyte apoptosis and other vascular pathology: diabetic Prkcd -/-mice are protected from pericyte loss, the formation of acellular capillaries and increased retinal permeability. A potential technical limitation of our work is that analyses of acellular capillaries and pericyte ghosts are performed after trypsin digestion and are morphological measures that imply the absence of pericytes, but these analyses cannot be definitively interpreted for identifying the cell type that died or the mechanism of cell death.
Our in vivo studies showed that PKC-δ activation leads to PDGF resistance in the retinas of diabetic mice; such resistance was not observed in Prkcd -/-mice. Moreover, specific inhibition of PKC-δ in pericytes in vitro or disruption of Prkcd in mice in vivo prevented SHP-1 expression and NF-κB activation, indicating that PKC-δ acts upstream of pathways mediated by both of these proteins. These findings identify a pivotal role for PKC-δ activation in causing pericyte apoptosis and the formation of acellular capillaries.
Multiple stimuli have been reported to increase the rate of PKC-δ gene transcription or to activate PKC-δ protein, including oxidative stress, ultraviolet light and other stresses 27 . Here, activation of PKC-δ and its elevated protein abundance persist in pericytes cultured from diabetic mice and rats, even after normoglycemia has been reinstituted. Our data suggest that chronic activation of PKC-δ is probably caused by effects on gene transcription rather than protein activation, as increased diacylglycerol concentrations are not maintained after switching high-glucose conditions to low-glucose conditions. However, it is possible that local and transient production of diacylglycerol may be sufficient to maintain PKC activity. In addition, high glucose seems to increase the rate of PKC-δ transcription, as expression of PKC-δ protein increases without parallel changes in the half-life of PKC-δ mRNA. Although the mechanisms underlying the persistent elevation of PKC-δ protein levels in pericytes are currently unclear, this finding is reminiscent of the persistent activation of NF-κB induced by hyperglycemia observed in monocytes, endothelial and smooth muscle cells, which has been attributed to epigenetic modification of histone methylation [28] [29] [30] .
Our results suggest that a specific target of PKC-δ signaling leading to cellular apoptosis is p38α MAPK, whereas the p38β isoform does not seem to be involved. Several mechanisms could explain the activation of p38α MAPK by PKC-δ, including direct and, possibly, indirect activation of MAPK 13 . Our results are consistent with previous studies that have shown that p38α MAPK activation can be used as a proapoptotic marker, whereas p38β MAPK has been mainly associated with cell migration, transcriptional regulation of Bcl-2 and antiapoptotic effects 31, 32 .
Our results show that high glucose-induced activation of PKC-δ and p38α MAPK can cause pericyte apoptosis through two different pathways: a pathway involving ROS induction of NF-κB activity, and a pathway involving deactivation of PDGFR-β. High glucoseinduced activation of p38α MAPK via NF-κB and the caspase pathway, causing apoptosis, has previously been reported 20 . This previous study and the results of our experiments using SOD-1-transgenic mice support the notion that oxidative stress induces the NF-κB pathway, which can cause pericyte apoptosis. However, we found a r t i c l e s that treatment with two inhibitors of NF-κB and antioxidant only partially inhibit high glucose-induced pericyte apoptosis and do not prevent high glucose-induced inhibition of PDGF-BB's actions on Akt and ERK activation. In contrast, inhibition of PKC-δ and p38α MAPK was able to prevent completely high glucose-or diabetesinduced pericyte apoptosis. These results suggest that high glucose can induce pericyte apoptosis by acting downstream of p38α MAPK activation, partially via the known NF-κB cascade, and partially via an independent pathway that induces apoptosis through inhibition of the actions of PDGF.
Our findings identify SHP-1 as a previously unrecognized downstream target of PKC-δ and p38α MAPK. SHP-1 has been reported to downregulate several receptor tyrosine kinases, including PDGFR-β, the insulin receptor, the EGF receptor and VEGFR-2 17, [33] [34] [35] . Mice deficient in SHP-1 due to mutation have severe hematopoietic disruption leading to patch dermatitis, extramedullary hematopoiesis, splenomegaly and hemorrhagic pneumonitis resulting in death after several weeks 36, 37 . Therefore, we were not able to evaluate the consequences of SHP-1 deficiency in mice after 6 months of diabetes. SHP-1 may have direct effects on the retina, given that SHP-1-deficient mice show retinal photoreceptor dysfunction 38 . Notably, we found that dominant-negative SHP-1 or siRNA specific for SHP-1 in pericytes completely prevented high glucose-induced inhibition of PDGF signaling and induction of apoptosis. To our knowledge, we identify SHP-1 for the first time as a cellular target of p38α MAPK, which increases activity of the SP1 transcription factor and thereby increases SHP-1 expression. Increased levels of SHP-1, in turn, lead to induction of apoptosis via deactivation of the prosurvival action of growth factor receptors such as PDGFR-β, an NF-κB-independent pathway. Changes in SHP-1 expression in diabetic mice and rats, measured using cultured pericytes derived from these animals or using uncultured pericytes captured by retinal laser microdissection, indicated that changes in SHP-1 expression are sustained and are cell-type selective. Changes in SHP-1 expression are also found in other cell types and tissues in diabetic animals, such as RPE and perivascular cells (glial cells) in the retina and in renal podocytes, suggesting a more widespread involvement of SHP-1 in diabetic pathology. Based on our results, high glucose-induced PKC-δ and SHP-1 activation could cause cellular apoptosis, a common cellular feature of diabetic vascular complications involving the retina, renal glands and cardiovascular tissue.
In summary, we show that hyperglycemia activates two independently acting pathways-the first involving PKC-δ and p38α MAPKmediated activation of SHP-1, resulting in PDGFR-β deactivation, and the second NF-κB-activation-to cause pericyte apoptosis in cultured cells and to initiate diabetic retinopathy in vivo. These findings identify several potential new therapeutic targets for the treatment of retinopathy and potentially other vascular complications of diabetes.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
